At Synlogic, we are working to develop potential biotherapeutics based on synthetic biology to treat disease in new ways.  We know patients are waiting for new treatment options and we are working tirelessly to make a difference.

Clinical trials are a critical way to study new drugs and advance research. They are a required step to bring any potential new therapy to those in need. Patient community participation in clinical trials can improve the clinical trial process in many ways. Patients help to advance understanding of disease and could affect how patients are treated for generations to come. Without patient involvement, new drugs cannot be approved.

We know that participating in a clinical trial is not always easy. We are grateful to the participants in our programs and in clinical trials around the world. They are true partners in science and innovation as we work together to create potential new treatment options.

To stay updated on Synlogic’s research and ongoing and/or future clinical trials, and other company updates, please email:

Phenylketonuria (PKU) Clinical Trial Program

People living with PKU are not able to break down the amino acid phenylalanine (Phe) found in the natural protein in many foods, including all meat and dairy, as well as breads and cereals. The buildup of Phe can be neurotoxic, meaning dangerous for the brain. Synlogic has developed a potential therapy for PKU that has been designed to break down Phe. The potential therapy is a specially engineered probiotic that is taken orally (as a powder, mixed with a liquid like water). Synlogic has a clinical trial program, called Synpheny, to evaluate this potential therapy.

For more information about Synlogic’s PKU clinical trials or for information related to PKU, or to share your story, please email: 

Homocystinuria (HCU) Clinical Trial Program

In 2021, we announced a new potential drug candidate for HCU called SYNB1353. SYNB1353 was designed to consume methionine, with the goal of lowering homocysteine levels in people living with HCU, thereby lowering the risk of serious complications. It is a specially engineered probiotic that is taken orally (as a powder, mixed with a liquid like water).

Synlogic has dosed its first healthy volunteers in its Phase 1 study of SYNB1353 to assess its safety in humans. This study will not be conducted in people living with HCU, but the data collected will be important in advancing SYNB1353 to further clinical trials.

For more information about the study, to learn more about upcoming HCU clinical trials or information related to HCU, or to share your story, please email:

Enteric Hyperoxaluria (EH) Clinical Trial Program

Enteric hyperoxaluria (EH) is a well-recognized cause of recurrent kidney stones. It is a chronic, progressive disease caused by different gastrointestinal (GI) conditions, such as surgery or inflammatory bowel disease like Crohn’s disease. SYNB8802 is an investigative therapy that Synlogic designed to break down oxalate in the GI tract, which then lowers levels of oxalate in the urine, thereby lowering the risk of crystal formation.

To date, Synlogic has shown that SYNB8802 has achieved proof of mechanism in healthy volunteers (a Phase 1 study). The company continues to study SYNB8802. For more information about the study (NCT04629170) and potential participation, click here.

To receive updates regarding Synlogic’s work on recurrent kidney stones, please email:

For Physicians

For more information on any Synlogic-sponsored clinical trials, please contact our clinical operations team at